A Blood Test for Alzheimer’s You Can Do at Home. The FDA Approval Process Explained.

Last updated 2 weeks ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

A finger-prick blood test can now detect Alzheimer’s proteins with 86% accuracy from a sample you collect at home and mail to a lab—no refrigeration required. Researchers recently announced this breakthrough after evaluating 337 people across seven European medical centers.

The DROP-AD study, published in Nature Medicine, found that these finger-prick samples matched the accuracy of standard blood draws. Participants at the University of Exeter collected their own samples after watching staff demonstrate the technique and reading written instructions. No phlebotomist required.

But here’s the catch: no timeline for when you’ll be able to order one. No information on cost. And no certainty the FDA will even allow it.

Between a promising research study and a test you can use sits the entire regulatory apparatus of the U.S. Food and Drug Administration. This process typically takes years and requires answering questions the DROP-AD researchers haven’t addressed yet. Questions like: How does the test perform when someone stores the card on a hot dashboard for three days? Or doesn’t prick deep enough? And what do you tell a 55-year-old with no symptoms who tests positive for Alzheimer’s proteins when there’s no approved treatment for people without symptoms?

For anyone hoping to get screened soon, understanding that gap matters more than the breakthrough itself.

What the Research Showed

The DROP-AD study measured three proteins that appear in the brain when Alzheimer’s is developing: phosphorylated tau-217 (p-tau217), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). The first one—p-tau217—is the star performer. It identified Alzheimer’s-related changes in the fluid around your brain and spinal cord with 86% accuracy. The finger-prick samples showed strong correlation with results from standard blood draws at a doctor’s office.

Labs are already measuring the same biomarkers in FDA-cleared diagnostics—like Quest Diagnostics’ AD-Detect panels, which show 91% sensitivity and specificity. Now they can be extracted from a sample you collect yourself and mail in a regular envelope.

The researchers emphasize it’s a research tool, not a clinical diagnostic. They note it could help study Parkinson’s, multiple sclerosis, and ALS. They point out it could enable large-scale studies in populations that never make it to academic medical centers—people with Down syndrome who face elevated risk, or anyone living more than an hour from a major hospital.

FDA Classification of Medical Devices

The FDA groups medical devices by how risky they are. Class I devices are lower-risk items, Class III devices are high-risk devices like pacemakers that need the most stringent approval process, and Class II devices are moderate risk with moderate review requirements.

An at-home diagnostic for this disease would almost certainly land in Class II, possibly Class III. That classification determines everything: how long approval takes, what evidence regulators require, whether the diagnostic needs full premarket approval or can demonstrate it’s similar enough to existing options that it doesn’t need full approval.

Several blood diagnostics for this condition already have FDA clearance or approval—C2N Diagnostics’ PrecivityAD2 test achieves 90% accuracy in patients with memory loss. Quest’s panels are already being used in clinical practice. So a manufacturer could theoretically argue their at-home version is similar enough to these lab-based options to use the faster approval process instead of the slower one.

Regulators have historically been skeptical of that argument for home collection. “Similar enough” means the new device doesn’t introduce new safety or efficacy concerns. Home collection introduces concerns that don’t exist when a trained phlebotomist draws your sample in a controlled clinical setting.

Consider the variables: insufficient sample from a shallow prick, cards sitting in hot mailboxes for two days, contamination, medications that interfere with the diagnostic that nobody told you to stop taking first.

These are the exact questions regulators will ask, and they’ll want data—lots of it—showing the diagnostic works reliably despite all those variables.

Clinical Trial Fraud and Regulatory Skepticism

In January 2026, the same month the DROP-AD results came out, Science magazine published an investigation that should concern anyone developing diagnostics for this disease.

Multiple drug companies discovered that clinical trial sites in South Florida had been fabricating data on a massive scale. Patients in placebo groups were reported as improving—impossible, since the disease only progresses. Many participants didn’t have the condition at all. Samples that supposedly came from people who’d taken an experimental drug contained no trace of that drug.

T3D Therapeutics called it a “nightmare scenario” and wrote off a $35 million trial. Annovis Bio found that 40% of volunteers in its trial had to be excluded because they didn’t have the disease—all recruited from Miami-area sites. BioVie abandoned its entire program after discovering that 15 South Florida sites had submitted data so obviously fraudulent it included brain scans copied and pasted between patient records.

The sites had been paying people to pretend they had cognitive impairment. Participants were intentionally drawing clocks incorrectly on screening assessments. Many were enrolled in multiple trials simultaneously, collecting payments from each.

Regulators now know about this. They’ve issued warnings. They’re investigating. And they’ve become substantially more skeptical of any data related to this disease, particularly data that comes from trial sites they can’t directly monitor.

For at-home diagnostic developers, this means the bar got higher. Regulators will want independent validation. They’ll want proof that the data supporting your diagnostic came from real patients with real disease. They’ll want quality assurance procedures that would catch the kind of fraud that fooled multiple drug companies.

Three Types of Validation Required

The FDA requires three types of validity before approving a diagnostic. The DROP-AD study only addresses one of them.

Analytical validity means the diagnostic accurately measures what it claims to measure. The DROP-AD research demonstrates this—finger-prick samples gave similar p-tau217 readings as standard draws. Regulators will want data showing the diagnostic works when someone collects the sample wrong, when it sits in transit for a week, when it’s exposed to temperature extremes. Real-world conditions, not ideal research conditions.

Clinical validity means the results correlate with disease presence or absence. Quest’s three-biomarker panel shows 88% positive predictive value and 91% negative predictive value in people with memory complaints—meaning if you have a positive result, there’s an 88% chance you have the pathology, and if you have a negative result, there’s a 91% chance you don’t. Those numbers meet the thresholds recommended by the Alzheimer’s Association for clinical use.

For an at-home diagnostic, regulators will want proof that home collection doesn’t degrade those numbers. That means validation studies comparing home-collected samples against the gold standards: brain imaging or a spinal tap that directly measures disease.

Clinical utility means proving that giving someone their results improves outcomes or enables better decisions. For people with no symptoms, we don’t know if that’s true.

Screening Asymptomatic People

About 10% of people over 70 have pathology in their brains but no symptoms yet. The proteins are accumulating. The disease process has started. They don’t know it.

Right now, there’s no FDA-approved treatment for people with signs of early disease when there’s no proven way to prevent it. The disease-modifying drugs approved in 2023 and 2024—lecanemab (Leqembi) and donanemab (Kisunla)—are only approved for people with mild cognitive impairment or mild dementia. If you’re cognitively normal, you can’t get them, even if your biomarkers say the disease is developing.

Clinical trials are evaluating whether treating people earlier—before symptoms appear—works better. Eli Lilly and others are enrolling asymptomatic people with positive biomarkers to find out. But those results are years away.

So how do regulators handle an at-home diagnostic that could identify millions of asymptomatic people with early pathology when there’s nothing proven to offer them?

The optimistic case: early identification enables participation in prevention trials, motivates beneficial lifestyle changes, allows people to plan for their future while they’re still cognitively intact.

The pessimistic case: you’re telling healthy people they have an incurable brain disease for which no preventive treatment exists, creating years of anxiety and potentially harmful self-directed interventions, all with no clear evidence that knowing helps.

Regulators have to weigh this. Their historical pattern suggests caution—they’re more likely to approve diagnostics for people who already have symptoms and could benefit from existing treatments than for asymptomatic screening where clinical utility remains unproven.

An at-home diagnostic might get approved for people with memory complaints before it’s approved for worried-but-healthy people who want to know their status.

Direct-to-Consumer Testing and Counseling

A 2024 survey commissioned by Siemens Healthineers found that 37% of adults have requested a lab analysis based on something they learned from family, friends, or the internet. Nearly 19% requested analyses based on social media.

Of people who pursued home screening or self-prescribed analyses, 49% didn’t share the results with a healthcare provider.

The direct-to-consumer lab market is projected to reach $7.7 billion by 2035. People want control over their health information. They want to request analyses on their own. And companies are happy to sell them.

Screening for this disease is different from cholesterol or vitamin D levels. A positive result means you have a progressive, incurable neurodegenerative disease. That’s information that requires counseling, context, and connection to appropriate care.

Consider someone who purchases an at-home diagnostic through a website, gets a positive result, and has no relationship with a neurologist. No understanding of the numbers. No access to the specialists who could determine whether they’re experiencing symptoms or have biomarker changes.

Regulators worry about this. And it influences how they regulate direct-to-consumer diagnostics, particularly for serious diseases.

They might require that results go through a physician. They might require talking to a genetic counselor or neurologist before you get results. They might restrict marketing to prevent companies from selling these diagnostics directly to consumers with no oversight.

All of which would slow down availability and potentially limit access—but might prevent the scenario where millions of people get devastating news through a website with no support system in place.

Laboratory Certification Requirements

There’s another regulatory layer most people don’t know about: federal lab quality rules, established by the Clinical Laboratory Improvement Amendments of 1988.

Any lab that runs health tests must meet federal quality standards. This includes the lab that would analyze your mailed-in sample.

CLIA classifies diagnostics by complexity. “Waived” options are simple enough that anyone can perform them with minimal training—think home pregnancy screenings or glucose monitors. These can be used anywhere, by anyone, with minimal regulatory oversight.

“Non-waived” options require more sophisticated laboratory infrastructure, trained personnel, quality control procedures, and regular inspections.

For an at-home diagnostic to achieve maximum accessibility—available through pharmacies, retail clinics, primary care offices, or direct-to-consumer—it would need approval to be used anywhere with no special lab equipment.

Getting approval to use a test that measures multiple proteins and provides a percentage chance of disease is a hard sell. Regulators and CMS (which administers CLIA) would need to determine that the diagnostic is simple enough and the interpretation straightforward enough that it doesn’t require specialized laboratory expertise.

More likely, these diagnostics will require certification that means only specialized labs can run them. You could collect the sample at home and mail it in—that’s what the DROP-AD research demonstrated—but the analysis would happen in a regulated lab environment, not at a retail pharmacy or doctor’s office.

It ensures quality. But it does mean the vision of truly democratized, widely accessible screening faces practical limitations.

Realistic Approval Timeline

The DROP-AD research, published in January 2026, proves the concept works. Before any company submits to regulators, they need additional studies specifically addressing real-world home collection conditions, diverse populations, and larger validation cohorts. That’s 12 to 18 months of additional research.

Then comes pre-submission meetings with regulators—four to eight weeks to get feedback on agency expectations for a formal application.

Then the submission itself. If it goes through the faster approval process (showing it works the same way as existing lab options), the standard review is 90 days. Complex submissions routinely get requests for additional information, extending that to 120-180 days or longer.

If regulators determine the diagnostic requires full premarket approval—the more stringent pathway for higher-risk devices—the standard review is 180 days. Most applications receive requests for additional data that extend the timeline to 18 months to three years.

A company starting FDA engagement in mid-2026 wouldn’t see approval before 2028 at the earliest. More likely 2029 or 2030.

Regulators can fast-track important new technologies that address unmet needs, potentially enabling expedited review. An at-home diagnostic might qualify if they agree it dramatically expands access to previously unavailable capabilities.

Fast-tracking doesn’t skip the need for proof the test works. It means regulators will review your submission faster once you have all that evidence.

Access and Healthcare Infrastructure

Right now, diagnostics for this disease are primarily available through specialized neurology or memory clinics at academic centers. You need a referral. You need insurance that covers it or the ability to pay out of pocket. You need to live somewhere near a major hospital.

At-home screening theoretically solves the geography problem—you can be anywhere and mail in a sample. But it doesn’t solve the problem of getting actual medical care.

Consider someone in rural Mississippi who purchases a diagnostic, gets a positive result, and there’s no neurologist within 100 miles. Or someone with no insurance who gets results indicating they need a $26,000-per-year medication they can’t afford.

The diagnostic becomes available, but the infrastructure to respond to the results doesn’t exist. That’s creating a new category of people who know they’re sick but can’t access care.

Quest Diagnostics already faces this problem. Their AD-Detect panels are FDA-cleared and clinically available, but Medicare and many commercial insurers don’t cover them yet. New payment rules have cut what labs get paid by up to 15%, and labs are warning that further cuts will “stifle innovation that benefits patient care.”

Even when diagnostics are FDA-approved and clinically validated, payment policy determines who gets access.

At-home screening doesn’t fix that. It might make it worse, by creating a two-tier system where affluent people can purchase diagnostics and pay for follow-up care while everyone else gets results they can’t act on.

We need to build the care infrastructure simultaneously, not as an afterthought.

What’s Available Today

If you’re worried about this disease—because of family history, because you’re noticing memory changes, because you’re anxious about it—here’s what’s available today:

Talk to your doctor. If you’re experiencing symptoms, several FDA-cleared diagnostics already exist. They’re not at-home options, but they’re less invasive than spinal taps and cheaper than PET scans. Quest’s AD-Detect panels and C2N’s PrecivityAD2 test are both available through physician request.

If you’re not experiencing symptoms, the clinical value of screening is unclear. You might qualify for a prevention trial—several are enrolling—but outside that context, knowing you have signs of early disease when there’s no proven way to prevent it is a personal decision with no clear right answer.

Don’t order online genetic tests that claim to predict your risk based on one gene. The APOE4 variant does raise your chances, but most people with APOE4 never develop the disease, and many people who do develop it don’t have the variant. It’s not diagnostic, and getting that information with no genetic counseling often creates more anxiety than insight.

Don’t wait for at-home diagnostics to become available before addressing modifiable risk factors. The same things that reduce cardiovascular risk—exercise, controlling blood pressure and cholesterol, not smoking, managing diabetes—also reduce risk for this disease. You don’t need a biomarker diagnostic to justify doing those things.

Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.